Bottom line
EUGAX vs BBEU: the short answer
EUGAX (Morgan Stanley Europe Opportunity Fund Inc.) and BBEU (JPMorgan BetaBuilders Europe ETF) are both mutual funds.
BBEU is cheaper at 0.09% vs 1.38% — a difference of $129 a year per $10,000 invested.
Over five years, BBEU returned +10.6% a year vs −1.2% for EUGAX.
EUGAX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
EUGAX vs BBEU side by side
| EUGAX | BBEU | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Morgan Stanley | J.P. Morgan |
| Category | Single Country / Region | Single Country / Region |
| Expense ratio | 1.38% | 0.09% |
| Annual cost per $10k | $138 | $9 |
| 10-yr cost on $10k (prospectus) | $2,412 | $115 |
| Max front load | 5.25% | None |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +5.8% | +35.7% |
| 5-yr return (annualized) | −1.2% | +10.6% |
| 10-yr return (annualized) | +6.7% | — |
| Best quarter | +30.4% | +21.1% |
| Worst quarter | −26.2% | −24.9% |
| Net assets (fund) | — | $9.4B |
| Number of holdings | — | 362 |
| Portfolio turnover | 17% | 5% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | EUGAX | BBEU | Difference |
|---|---|---|---|
| 2025 | +11.6% | +35.7% | −24.1% |
| 2024 | +12.0% | +2.3% | +9.8% |
| 2023 | +24.8% | +20.0% | +4.8% |
| 2022 | −44.7% | −14.7% | −29.9% |
| 2021 | +15.3% | +16.7% | −1.4% |
| 2020 | +55.1% | +5.9% | +49.2% |
| 2019 | +26.9% | +23.8% | +3.0% |
Source: Fund prospectus bar charts
Holdings overlap
EUGAX and BBEU share none of their top holdings.
EUGAX top 10
BBEU top 10
- ASML Holding NV — 4.58%
- HSBC Holdings plc — 2.62%
- Roche Holding AG — 2.16%
- Novartis AG — 2.14%
- AstraZeneca plc — 1.89%
- Shell plc — 1.83%
- Nestle SA — 1.78%
- JPMorgan Securities Lending Money Market Fund — 1.78%
- Siemens AG — 1.68%
- Banco Santander SA — 1.46%
FAQ
What is the difference between EUGAX and BBEU?
Which is cheaper, EUGAX or BBEU?
Should I own both EUGAX and BBEU?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.